[version 1; peer review: 1 approved]
No competing interests were disclosed.
Gall bladder carcinoma (GBC) is a challenging malignancy characterized by late-stage diagnosis and poor prognosis. Early detection and accurate staging are crucial for improving patient outcomes. Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) offer non-invasive imaging modalities that may aid in the evaluation of GBC. Choline, a metabolite detected by MRS, has been implicated in tumor growth and may serve as a potential biomarker for GBC. This study aims to investigate the role of MRI and MRS in evaluating choline levels as biomarkers for GBC.
A prospective observational study will be conducted involving patients with suspected or confirmed GBC referred to the Department of Radiology, AVBRH, Sawangi. Patients meeting inclusion criteria will undergo MRI scans and MRS examinations to assess tumor characteristics and choline levels. Data collected will include MRI images, MRS spectra, histopathological results, and clinical outcomes. Statistical analysis will be performed to examine correlations between MRI findings, choline levels, and histopathological characteristics.
It is anticipated that MRI and MRS will demonstrate utility in evaluating choline levels as imaging biomarkers for GBC. Correlations between choline levels, tumor characteristics, and clinical outcomes are expected to provide valuable insights into the role of choline in GBC pathogenesis and prognosis. If successful, MRI and MRS could serve as non-invasive tools for early detection, staging, and treatment response monitoring in GBC, ultimately leading to improved patient outcomes and management strategies.
Gallbladder carcinoma (GBC) is a relatively rare but highly aggressive malignancy of the biliary tract with a poor prognosis, mainly due to its often late diagnosis and limited treatment options.
Recent advances in MRI, coupled with magnetic resonance spectroscopy (MRS), have shown promise in enhancing the diagnostic accuracy and prognostic value for various cancers, including hepatobiliary malignancies.
Despite the growing interest in utilizing MRI and MRS for GBC evaluation, there remains a need for further research to validate their utility, particularly regarding choline levels as a biomarker for tumor detection and characterization. Therefore, this study aims to investigate the role of MRI and MR spectroscopy in evaluating choline levels in GBC to improve early detection and guide personalized treatment strategies for this aggressive malignancy.
This study aims to investigate the role of MRI and MR spectroscopy in evaluating choline levels in gall bladder carcinoma.
To assess the spectrum of MRI findings in patients diagnosed with gall bladder carcinoma. To determine choline levels using MR spectroscopy in gall bladder carcinoma. To evaluate the diagnostic accuracy of MRI in assessing the size, resectability, and vascular involvement of gall bladder carcinoma. To explore the potential of MR spectroscopy in detecting choline levels as a biomarker for gall bladder carcinoma. To assess the feasibility and safety of performing MRI and MR spectroscopy in patients with gall bladder carcinoma. To investigate any correlation between choline levels detected by MR spectroscopy and histopathological findings in gall bladder carcinoma. To contribute to understanding the role of imaging techniques in the early detection and management of gall bladder carcinoma.
This study will utilize a prospective observational design to evaluate the role of MRI and MR spectroscopy in assessing choline levels in gall bladder carcinoma. Patients meeting the inclusion criteria will undergo MRI scans, and MR spectroscopy will be conducted to analyze choline levels. Data will be collected and analyzed to fulfill the study objectives.
The study population will include patients with suspected or diagnosed cases of gall bladder carcinoma. Inclusion criteria will involve patients who consent to participate, do not have contraindications for MRI or MR spectroscopy, and are referred to the Department of Radiology, AVBRH, Sawangi. Exclusion criteria will encompass patients with prior surgical or medical interventions, pregnant women, individuals with pacemakers or metallic implants, those with psychological conditions or claustrophobia, and those who are unwilling or uncooperative.
The study will be conducted at the Department of Radiology, Acharya Vinoba Bhave Rural Hospital, Sawangi, under the auspices of Datta Meghe Institute of Higher Education and Research. AVBRH has the necessary infrastructure and facilities for conducting MRI scans and MR spectroscopy. The hospital serves as a referral center for patients in the region, ensuring access to a diverse patient population for the study.
Patients aged 18 years and above. Patients with suspected or confirmed diagnosis of gall bladder carcinoma based on clinical evaluation, imaging studies, or biopsy results. Patients willing to provide verbal and written informed consent for participation in the study. Patients capable of undergoing MRI and MR spectroscopy examinations without contraindications. Patients referred to the Department of Radiology, AVBRH, Sawangi, for further evaluation and management of gall bladder carcinoma.
Patients below the age of 18 years. Patients with contraindications for MRI or MR spectroscopy, including those with metallic implants incompatible with MRI, pacemakers, cochlear implants, or other implanted devices. Pregnant women or women who are breastfeeding. Patients with a history of significant psychological conditions, including severe claustrophobia, that would impede the successful completion of the imaging procedures. Patients who are unwilling or unable to provide informed consent for participation in the study. Patients with prior surgical interventions or medical treatments for gall bladder carcinoma that may confound the study results. Patients with concurrent medical conditions or comorbidities that could affect the interpretation of MRI or MR spectroscopy findings or compromise patient safety during the procedures.
Data collection for this study will encompass several key components. Initially, baseline information will be gathered, including demographic data such as age, gender, ethnicity, and occupation, alongside a detailed clinical history. This will entail documenting symptoms, their duration, previous treatments, and any existing medical comorbidities. Laboratory investigations will also be recorded, including complete blood count, liver function tests, and tumor markers such as CA 19-9. Moreover, imaging reports from previous studies, such as ultrasounds or CT scans, will be reviewed to compile relevant findings related to gall bladder carcinoma. Subsequently, data collection will focus on MRI and MR spectroscopy. MRI images, including T1-weighted, T2-weighted, and diffusion-weighted images, will be obtained and assessed for various features indicative of gall bladder carcinoma, such as mass lesions or wall thickening. Additionally, MR spectroscopy data will be analyzed for choline peaks, providing quantitative measurements of choline concentration, a potential biomarker for gall bladder carcinoma.
Histopathological data, if available, will also be included in the analysis. This will involve documenting the results of biopsies or surgical specimens, including the histopathological diagnosis of gall bladder carcinoma, tumor grade (well, moderately, or poorly differentiated), and tumor stage based on TNM staging. Followup data will be collected to monitor treatment responses and clinical outcomes. This will entail documenting the treatments received, such as surgery, chemotherapy, or radiotherapy, and assessing responses through radiological evaluations of tumor regression, stabilization, or progression. Additionally, patient survival status, recurrence of carcinoma, and progression-free survival will be recorded.
Furthermore, the study will gather data on patient experiences and any adverse events encountered during MRI and MR spectroscopy procedures. Patient feedback regarding comfort levels and any discomfort or complications experienced will be documented to inform future improvements in patient care. Quality control measures will be implemented throughout the data collection process, including standardized imaging protocols, blinding of radiologists interpreting the data, and regular calibration of imaging equipment to ensure the accuracy and reliability of results. Finally, data management and analysis will involve entering collected data into a secure electronic database and statistical analysis using appropriate methods to examine relationships between variables. Ethical considerations, such as ensuring patient confidentiality, obtaining informed consent, and obtaining institutional review board approval, will be followed throughout the study.
Determining the appropriate sample size is crucial for ensuring the study’s statistical power and the reliability of the findings. This study’s sample size calculation was based on the prevalence of gall bladder carcinoma and the desired confidence level and margin of error. Using the Cochran Formula, a sample size of 20 patients was determined, considering a prevalence rate of 1.2% and an error margin of 5%. This sample size provides sufficient statistical power to detect potential associations between MRI findings, choline levels, and gall bladder carcinoma characteristics with high confidence.
The statistical analysis for this study will employ a range of methods to thoroughly examine the relationships between variables and assess the significance of the findings. Initially, descriptive statistics will be utilized to summarize the characteristics of the study population, encompassing demographic information, clinical features, and imaging findings. Measures such as means, standard deviations, frequencies, and percentages will be calculated to provide a comprehensive overview of the collected data, facilitating a clear understanding of the sample characteristics. Correlation analysis will then explore the strength and direction of relationships between key variables of interest. Specifically, correlations between MRI findings, choline levels measured by MR spectroscopy, and histopathological results will be assessed. Depending on the nature of the data, either Pearson correlation coefficients or Spearman’s rank correlation coefficients will be computed to quantify the degree of association between these variables. Regression analysis will be employed to investigate the predictive value of MRI findings and choline levels for various aspects of gall bladder carcinoma, such as tumor stage, grade, or treatment response. Multiple linear regression or logistic regression models may be utilized to determine the independent contributions of each variable in predicting specific outcomes, thereby elucidating their potential prognostic significance.
Furthermore, comparative analysis will be performed to evaluate differences in MRI findings and choline levels across different subgroups of patients, categorized based on relevant factors such as tumor stage, grade, or treatment status. This analysis will utilize appropriate statistical tests, including t-tests, Mann-Whitney U tests, ANOVA, chi-square tests, or Fisher’s exact tests, depending on the type and distribution of the data. Survival analysis techniques, such as Kaplan-Meier curves and Cox proportional hazards models, may be employed to assess the impact of MRI findings and choline levels on patient survival outcomes, including overall and progression-free survival. These analyses will provide valuable insights into the prognostic significance of imaging biomarkers in gall bladder carcinoma. Additionally, receiver operating characteristic (ROC) analysis may be conducted to evaluate the diagnostic accuracy of MRI findings and choline levels in distinguishing between different stages or grades of gall bladder carcinoma. By calculating the area under the curve (AUC) values, the discriminatory power of these imaging biomarkers can be quantified, informing their clinical utility in disease diagnosis and management using R studio version 4.3.1.
After the completion of the study, we will publish it in an indexed journal or conference.
The study has yet to start. After the publication of the protocol, we will start recruiting for the study.
Gall bladder carcinoma (GBC) poses a significant clinical challenge due to its often-asymptomatic nature in the early stages and aggressive behavior once symptomatic. Despite advancements in diagnostic modalities and treatment strategies, the prognosis for GBC remains poor, primarily due to late-stage diagnosis and limited effective treatment options.
The use of MRI in the evaluation of GBC has shown promising results in previous studies. MRI provides high-resolution imaging of the gall bladder, allowing for detailed assessment of tumor size, local invasion, and vascular involvement. Additionally, MR spectroscopy offers the ability to measure choline levels within the tumor tissue, which may indicate malignancy. Choline is a key component of cell membrane metabolism and has been implicated in tumor growth and proliferation. Several studies have demonstrated elevated choline levels in various malignancies, including breast, prostate, and brain tumors.
Our study aims to build upon this knowledge by investigating the utility of MRI and MR spectroscopy in evaluating choline levels, specifically in GBC. By correlating MRI findings with choline levels measured by MR spectroscopy, we aim to identify imaging biomarkers that can aid in the early detection and characterization of GBC. Early detection is critical in improving patient outcomes, as surgical resection remains the primary curative treatment option for GBC. Moreover, accurate tumor aggressiveness and staging characterization can guide treatment decisions and prognosis prediction.
The proposed study will contribute to the growing body of literature on imaging biomarkers for GBC and may have implications for clinical practice. If successful, MRI and MR spectroscopy could be non-invasive tools for GBC diagnosis and staging, potentially reducing the need for invasive procedures such as biopsy or exploratory surgery. Additionally, quantifying choline levels in GBC tumors could aid treatment response monitoring and prognostication, leading to more personalized and effective patient management strategies.
However, several challenges and limitations must be considered. Firstly, the sample size in our study is relatively small, which may limit the generalizability of our findings. Future studies with larger cohorts are warranted to validate our results and establish robust diagnostic and prognostic models.
The Institutional Ethics Committee of Datta Meghe Institute of Higher Education and Research (DU) has approved the study protocol (Reference number: DMIHER/IEC/2023/768. Date: 21-03-2023). Before commencing the study, we will obtain written informed consent from all participants, providing them with a comprehensive explanation of the study’s objectives.
No data are associated with this article.
Is the study design appropriate for the research question?
Yes
Is the rationale for, and objectives of, the study clearly described?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Reviewer Expertise:
Oncology
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.